Skip to main content

Susan Kay Murphy, PhD

Property title
Associate Professor in Obstetrics and Gynecology
Campus Mail: 119 B Wing LSRC, 308 Research Drive, Durham, NC 27708
Phone: (919) 681-3423
Email: susan.murphy@duke.edu

Ovarian and cervical cancer epigenetics, imprinted genes in ovarian and cervical cancers, identification of methylation biomarkers of disease, ovarian cancer stem cells, chemotherapeutic response in ovarian cancer, tumor dormancy, the influence of the in utero environment on DNA methylation and risk of disease.

Education and Training

  • Ph.D., Wake Forest University, 1998
  • B.A., University of North Carolina at Charlotte, 1992

Selected Grants and Awards

Publications

Matsumura, Noriomi, Zhiqing Huang, Tsukasa Baba, Paula S. Lee, Jason C. Barnett, Seiichi Mori, Jeffrey T. Chang, et al. “Yin yang 1 modulates taxane response in epithelial ovarian cancer..” Mol Cancer Res 7, no. 2 (February 2009): 210–20. https://doi.org/10.1158/1541-7786.MCR-08-0255.

Full Text

Baba, T., P. A. Convery, N. Matsumura, R. S. Whitaker, E. Kondoh, T. Perry, Z. Huang, et al. “Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells..” Oncogene 28, no. 2 (January 15, 2009): 209–18. https://doi.org/10.1038/onc.2008.374.

Full Text

Lee, P. S., V. Teaberry, A. E. Bland, Z. Huang, A Alvarez Secord, A. Berchuck, and S. K. Murphy. “MAL, a gene associated with survival in epithelial ovarian cancer, is epigenetically regulated.” In Gynecologic Oncology, 108:S125–S125. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2008.

Scholars@Duke

Matsumura, N., Z. Huang, T. Perry, D. Kroyer, T. Baba, S. Mori, S. Fujii, A. Berchuck, and S. K. Murphy. “Methylation in ovarian cancer is related to poor prognosis and suppression of the transforming growth factor signaling pathway.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S104–S104.

Scholars@Duke

Bernardini, M. Q., P. Lee, T. Baba, R. S. Whitaker, S. K. Murphy, and A. Berchuck. “Microarray analysis defines patterns of gene expression associated with mutation of TP53 in ovarian cancer.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S84–S84.

Scholars@Duke

Baba, T., S. Mori, N. Matsumura, M. Bernardini, S. Fujii, A. Berchuck, and S. K. Murphy. “Microarray analysis identifies NSC668814 as a potentially active chemotherapeutic agent for platinum-resistant ovarian cancers with TP53 mutations.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S72–S72.

Scholars@Duke

Baba, T., P. A. Convery, N. Matsumura, R. S. Whitaker, T. Perry, Z. Huang, S. Mori, et al. “Stem cell marker CD133 (PROMININ-1) is epigenetically regulated in ovarian cancer.” In Gynecologic Oncology, 108:S104–S104, 2008.

Scholars@Duke

Kondoh, E., T. Baba, N. Matsurnura, S. Fujii, A. Berchuck, and S. K. Murphy. “Targeting dormant ovarian cancer cells.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S13–14.

Scholars@Duke

Baba, Tsukasa, Patricia Convey, Noriomi Matsumura, Regina S. Whitaker, Tiffany Perry, Zhiqing Huang, Seiichi Mori, et al. “Stem cell marker CD133 (PROMININ-1) is epigenetically regulated in ovarian cancer.” In Cancer Biomarkers, 4:175–76, 2008.

Scholars@Duke

O’Sullivan, Fiona M., Susan K. Murphy, Lauren R. Simel, Amanda McCann, John J. Callanan, and Catherine M. Nolan. “Imprinted expression of the canine IGF2R, in the absence of an anti-sense transcript or promoter methylation..” Evol Dev 9, no. 6 (November 2007): 579–89. https://doi.org/10.1111/j.1525-142X.2007.00198.x.

Full Text

Pages